IXHL

IXHL

USD

Incannex Healthcare Inc. Common Stock

$0.339-0.005 (-1.480%)

即時價格

Healthcare
Drug Manufacturers - Specialty & Generic
澳洲

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$0.344

最高

$0.349

最低

$0.336

交易量

15.84M

公司基本面

市值

118.0M

行業

Drug Manufacturers - Specialty & Generic

國家

Australia

交易統計

平均交易量

66.44M

交易所

NCM

貨幣

USD

52週範圍

最低 $0.08當前 $0.339最高 $3.12

相關新聞

GlobeNewswire

Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

MELBOURNE, Australia and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company") is pleased to report positive data from its Phase 2 clinical trial of PSX-001

查看更多
Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder
GlobeNewswire

Incannex Healthcare Authorizes $20 Million Share Repurchase Program

MELBOURNE, Australia and NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative combination

查看更多
Incannex Healthcare Authorizes $20 Million Share Repurchase Program
GlobeNewswire

Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

MELBOURNE, Australia and NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage pharmaceutical company developing innovative combination therapies for prevalent medical

查看更多
Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea